Matching articles for "amoxicillin/clavulanate"
Issue 1745 · January 5, 2026
Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI

The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients…

Med Lett Drugs Ther. 2026 Jan 5; 68(1745):1-3 doi:10.58347/tml.2026.1745a
The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Issue 1741 · November 10, 2025
Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs

Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):179-80 doi:10.58347/tml.2025.1741b
Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis in women who have limited or no alternative oral antibacterial treatment options. It is the first oral penem-containing product to be approved in the US.
Issue 1674 · April 17, 2023 Free
Treatment of Common Respiratory Tract Infections

Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens.…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):57-62 doi:10.58347/tml.2023.1674a
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Issue 1643 · February 7, 2022
Drugs for Acute Otitis Media in Children

More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of…

Med Lett Drugs Ther. 2022 Feb 7; 64(1643):22-3
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of the tympanic membrane.
Issue 1616 · January 25, 2021 Free
Antibacterial Drugs for Community-Acquired Pneumonia

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):10-5
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Issue 1547 · May 21, 2018
Clarithromycin in Patients with Coronary Artery Disease

The FDA has warned that use of the macrolide antibiotic clarithromycin ( Biaxin , and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.

Med Lett Drugs Ther. 2018 May 21; 60(1547):89-90
The FDA has warned that use of the macrolide antibiotic clarithromycin ( Biaxin , and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
Issue 1532 · October 23, 2017
Drugs for Common Bacterial Infections in Adults

Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):171-7
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Issue 1496 · June 6, 2016
Alternatives to Fluoroquinolones

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):75-6
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Issue 131 · July 1, 2013
Drugs for Bacterial Infections

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of…

Treat Guidel Med Lett. 2013 Jul; 11(131):65-74
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Issue 1396 · August 6, 2012
Tablet Splitting

Breaking drug tablets in half is a common practice. Since our last article on this subject, some new data have become available.

Med Lett Drugs Ther. 2012 Aug 6; 54(1396):63
Breaking drug tablets in half is a common practice. Since our last article on this subject, some new data have become available.
Issue 1395 · July 23, 2012
Drugs for Urinary Tract Infections

The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):57-8
The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in non-pregnant women focus on the unnecessary use of fluoroquinolones to treat uropathogens that are increasingly becoming resistant to them. Resistance of Escherichia coli to ciprofloxacin in the US has increased from 3% in 2000 to 17.1% in 2010.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.